No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
GEM-CAP Sensitive: A2 - Guideline
|
GEM-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
GEM-CAP Sensitive: A2 - Guideline
|
GEM-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
KIT mutation
|
Thymic Carcinoma
|
KIT mutation
|
Thymic Carcinoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
VIP Sensitive: A2 - Guideline
|
VIP Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
VIP Sensitive: A2 - Guideline
|
VIP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CAP Sensitive: A2 - Guideline
|
CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
ADOC Sensitive: A2 - Guideline
|
ADOC Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
CAP + prednisone Sensitive: A2 - Guideline
|
CAP + prednisone Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
CAP Sensitive: A2 - Guideline
|
CAP Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
CAP + prednisone Sensitive: A2 - Guideline
|
CAP + prednisone Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
ADOC Sensitive: A2 - Guideline
|
ADOC Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
pembrolizumab Resistant: A2 - Guideline
|
pembrolizumab Resistant: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
etoposide oral Sensitive: A2 - Guideline
|
etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
prednisone + octreotide Sensitive: A2 - Guideline
|
prednisone + octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
octreotide Sensitive: A2 - Guideline
|
octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
No biomarker
|
Thymic Carcinoma
|
No biomarker
|
Thymic Carcinoma
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
prednisone + octreotide Sensitive: A2 - Guideline
|
prednisone + octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
octreotide Sensitive: A2 - Guideline
|
octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Thymoma
|
No biomarker
|
Thymoma
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
EIF4EBP1 expression
|
Thymic Carcinoma
|
EIF4EBP1 expression
|
Thymic Carcinoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
HER-2 positive
|
Thymic Carcinoma
|
HER-2 positive
|
Thymic Carcinoma
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Thymic Carcinoma
|
HER-2 mutation
|
Thymic Carcinoma
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
IGF1R expression
|
Thymoma
|
IGF1R expression
|
Thymoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
IGF1R expression
|
Thymic Carcinoma
|
IGF1R expression
|
Thymic Carcinoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
EIF4EBP1 expression
|
Thymoma
|
EIF4EBP1 expression
|
Thymoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
KIT D820Y
|
Thymic Carcinoma
|
KIT D820Y
|
Thymic Carcinoma
|
sorafenib Sensitive: C4 – Case Studies
|
sorafenib Sensitive: C4 – Case Studies
|
PD-L1 overexpression
|
Thymic Carcinoma
|
PD-L1 overexpression
|
Thymic Carcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
PD-L1 overexpression
|
Thymic Carcinoma
|
PD-L1 overexpression
|
Thymic Carcinoma
|
pembrolizumab Resistant: C4 – Case Studies
|
pembrolizumab Resistant: C4 – Case Studies
|
PD-L1 overexpression
|
Thymoma
|
PD-L1 overexpression
|
Thymoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
EGFR exon 20 insertion
|
Thymic Carcinoma
|
EGFR exon 20 insertion
|
Thymic Carcinoma
|
anlotinib Sensitive: C4 – Case Studies
|
anlotinib Sensitive: C4 – Case Studies
|
EGFR exon 19 deletion
|
Thymic Carcinoma
|
EGFR exon 19 deletion
|
Thymic Carcinoma
|
icotinib Sensitive: C4 – Case Studies
|
icotinib Sensitive: C4 – Case Studies
|
MSLN expression
|
Thymic Carcinoma
|
MSLN expression
|
Thymic Carcinoma
|
BAY 94-9343 Sensitive: D – Preclinical
|
BAY 94-9343 Sensitive: D – Preclinical
|